Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
Firas Kreidieh, Hussein A. Tawbi
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Hyun Jee Kim, Yeong Ho Kim
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2984-2984
Open Access | Times Cited: 19
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications
Jie Wang, Yian Wang, Xianjie Jiang, et al.
Cancer Letters (2024) Vol. 588, pp. 216758-216758
Closed Access | Times Cited: 14
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Jingjing Su, Yiting Fu, Zitong Cui, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic
Yaser E. Alqurashi
Pathology - Research and Practice (2024) Vol. 254, pp. 155124-155124
Closed Access | Times Cited: 7
Exosome-mediated communication between gastric cancer cells and macrophages: implications for tumor microenvironment
Yue Qiu, Guimei Lu, Na Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Checkpoint Inhibitors in Dogs: Are We There Yet?
Antônio Giuliano, Pedro Antônio Bronhara Pimentel, Rodrigo dos Santos Horta
Cancers (2024) Vol. 16, Iss. 11, pp. 2003-2003
Open Access | Times Cited: 4
Leptomeningeal metastasis and cancer immunotherapy
Rob Smeyers, Alia Fazal-Salom, Ján Remšík
Elsevier eBooks (2025)
Closed Access
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
Xiaoli Zhou, Shunfeng Hu, Xin Wang
Genes & Diseases (2025), pp. 101599-101599
Open Access
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy
Qiongjie Hu, Yueli Shi, Huang Wang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Understanding and Overcoming Immunotherapy Resistance in Skin Cancer: Mechanisms and Strategies
Shreya Singh Beniwal, Amruta Radhakrishnan, Ayanchetty Haripraba, et al.
Aging and Cancer (2025)
Open Access
Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers
Chunjian Zuo, Jie Tian
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Development of Personalized Strategies for Precisely Battling Malignant Melanoma
Armond J. Isaak, G Clements, Rand Gabriel M. Buenaventura, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 4
Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
Xue Wang, Shanshan Ma, Shuting Zhu, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 225-225
Open Access
B7-H3 suppresses CD8+ T cell immunologic function through reprogramming glycolytic metabolism
Yulu Wu, Wenzhe Han, Xiufa Tang, et al.
Journal of Cancer (2024) Vol. 15, Iss. 9, pp. 2505-2517
Open Access | Times Cited: 3
Immune Checkpoint Inhibitors in Geriatric Oncology
Sarah Cook, Md Al Amin, Shahla Bari, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 562-572
Closed Access | Times Cited: 3
The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma
Pranav Volety, Carl A. Shirley, Gagan Chhabra, et al.
Photochemistry and Photobiology (2024) Vol. 100, Iss. 4, pp. 910-922
Open Access | Times Cited: 3
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)
Ahmed Mousa, Alexander Enk, Jessica C. Hassel, et al.
Cells (2024) Vol. 13, Iss. 19, pp. 1615-1615
Open Access | Times Cited: 3
Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma
Stephan Ledderose, Carola Ledderose, Georg Ledderose
Pathology - Research and Practice (2024) Vol. 260, pp. 155468-155468
Open Access | Times Cited: 2
Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes
Ting Li, Shichen Sun, Yubing Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Immune responses and immunotherapeutic approaches in the treatment against cancer
Stanley P. L. Leong
Clinical & Experimental Metastasis (2024) Vol. 41, Iss. 4, pp. 473-493
Open Access | Times Cited: 2
Case report: Conjunctival melanoma treated with relatlimab and nivolumab showing remarkable response
Mirona Attrash, Omar Badran, Yinon Shapira, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Predicting immunotherapy response in melanoma using a novel tumor immunological phenotype-related gene index
Shaoluan Zheng, Anqi He, Chenxi Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma
Xinyi Chen, Shabana Habib, Madalina Alexandru, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3260-3260
Open Access | Times Cited: 1
Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
Alexander C.J. van Akkooi
Annals of Surgical Oncology (2023) Vol. 31, Iss. 1, pp. 1-3
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top